Calixar SAS:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Calixar SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12372
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Calixar SAS (Calixar) is a provider of solutions to develop conformational antibodies. The company offers production, Solubilization, extraction, purification, stabilization and crystallization of functional membrane proteins and antigens. It offers technology to discover and validate the potential of new target antigens. Calixar’s technology also helps to produce immunogenic and native membrane antigens stabilized in solution; and to avoid the use of adjuvants. The company’s services include protein sequence analysis and design optimization, protein expression, structural and functionality tests, scale-up, crystallography tests, and 3D structure determination. It serves pharmaceutical and biotechnological companies and academic life sciences organizations. Calixar is headquartered in Lyon, France.

Calixar SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Calixar SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calixar SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Calixar SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Calixar SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Calixar SAS, Pharmaceuticals & Healthcare, Deal Details 9
Venture Financing 9
Calixar Raises USD1.1 Million in Series B Financing 9
Calixar Raises US$1 Million In Seed Financing 10
Partnerships 11
Advanced BioScience Enters Into Co-Marketing Agreement With Calixar 11
Calixar Enters Into Co-Development Agreement With Synthelis 12
Calixar SAS – Key Competitors 13
Calixar SAS – Key Employees 14
Calixar SAS – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 16
Government and Public Interest 16
Nov 28, 2017: CALIXAR and AstraZeneca to Publish New Insight on KCC2 Architecture and Function 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Calixar SAS, Pharmaceuticals & Healthcare, Key Facts 2
Calixar SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
Calixar SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calixar SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Calixar SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Calixar SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Calixar Raises USD1.1 Million in Series B Financing 9
Calixar Raises US$1 Million In Seed Financing 10
Advanced BioScience Enters Into Co-Marketing Agreement With Calixar 11
Calixar Enters Into Co-Development Agreement With Synthelis 12
Calixar SAS, Key Competitors 13
Calixar SAS, Key Employees 14
Calixar SAS, Other Locations 15

List of Figures
Calixar SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Calixar SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Calixar SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Calixar SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calixar SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Calixar SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★海外企業調査レポート[Calixar SAS:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Acceleron Pharma Inc (XLRN)-製薬・医療分野:企業M&A・提携分析
    Summary Acceleron Pharma Inc (AcceleronPharma) is a clinical stage biopharmaceutical company that discovers, developsand commercializes therapeuticsto treat serious and rare diseases. The company’s lead therapeutic candidate, luspatercept, is in phase 3 studyused for the treatment of the myelodyspla …
  • Galecto Biotech AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Galecto Biotech AB (Galecto Biotech) is a drug development company that focuses on the development of galectin modulators for the treatment of cancer, fibrosis and inflammation. The company develops activators and inhibitors of galectins. Its pipeline products include TD139 inhaled Gal -3 in …
  • Kier Group plc:企業のM&A・事業提携・投資動向
    Kier Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kier Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Pictet & Cie Group SCA:企業の戦略・SWOT・財務情報
    Pictet & Cie Group SCA - Strategy, SWOT and Corporate Finance Report Summary Pictet & Cie Group SCA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Marenica Energy Ltd (MEY):企業の財務・戦略的SWOT分析
    Summary Marenica Energy Ltd (MEY) is a mining and mineral resource exploration and development company that acquires, identifies, develops, and explores for lead, silver, zinc, copper, uranium and gold mineral properties in Australia. The company develops and operates uranium project using conventio …
  • 4SC AG (VSC):企業の財務・戦略的SWOT分析
    4SC AG (VSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Abzena Plc (ABZA):企業の財務・戦略的SWOT分析
    Summary Abzena Plc (Abzena), formerly Polytherics Group Ltd, is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include …
  • Forestar Group Inc:企業の戦略・SWOT・財務情報
    Forestar Group Inc - Strategy, SWOT and Corporate Finance Report Summary Forestar Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Eesti Energia AS-エネルギー分野:企業M&A・提携分析
    Summary Eesti Energia AS (Eesti Energia) is an international energy company that offers energy solutions ranging from electricity, heat and fuel production to sales, customer service and ancillary energy services among others. Eesti Energia sells electricity to the Baltic retail customers and the wh …
  • Interconexion Electrica SA ESP (ISA):企業の財務・戦略的SWOT分析
    Interconexion Electrica SA ESP (ISA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Astaldi Spa:企業の戦略・SWOT・財務分析
    Astaldi Spa - Strategy, SWOT and Corporate Finance Report Summary Astaldi Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG; BAY 1905254, COM902 and TIGIT; and autoimmune diseases pipeline includes CGEN …
  • Orly International, Inc.:企業の戦略・SWOT・財務情報
    Orly International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Orly International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • United Surgical Partners International Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary United Surgical Partners International Inc (United Surgical Partners) is a healthcare service provider that offers ambulatory surgical services. The center provides services in the therapeutical areas of orthopedic, pain management, gynaecology, general surgery, ear, nose, and throat, endosc …
  • Ei Towers SpA:企業の戦略・SWOT・財務分析
    Ei Towers SpA - Strategy, SWOT and Corporate Finance Report Summary Ei Towers SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • American International Group Inc:企業の戦略・SWOT・財務情報
    American International Group Inc - Strategy, SWOT and Corporate Finance Report Summary American International Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • MetLife, Inc.:企業のM&A・事業提携・投資動向
    MetLife, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's MetLife, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • SAG. Solar GmbH & Co KG-エネルギー分野:企業M&A・提携分析
    Summary S.A.G. Solar GmbH & Co. KG. (S.A.G. Solar), a subsidiary of Shunfeng International Clean Energy Limited, is a manufacturer of photovoltaic systems. The company constructs, installs, operates and integrates solar power plants. It constructs rooftop systems, roof and facade-integrated systems, …
  • Holland Colours NV (HOLCO):企業の財務・戦略的SWOT分析
    Holland Colours NV (HOLCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Power Assets Holdings Limited (6):電力:M&Aディール及び事業提携情報
    Summary Power Assets Holdings Limited (Power Assets) a subsidiary of CK Infrastructure Holdings Limited, is an investment holding company. The company through its subsidiaries, joint ventures, and affiliates, invests in power and utility-related businesses. The company has interests in electricity g …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆